0910-AF93 200904 Unified Agenda of Federal Regulatory and Deregulatory Actions 0910 Food and Drug Administration FDA 0900 Department of Health and Human Services HHS Use of Ozone-Depleting Substances; Removal of Essential Use Designations [Flunisolide, Triamcinolone, Metaproterenol, Pirbuterol, Albuterol and Ipratropium in Combination, Cromolyn, and Nedocromil] Other Significant Previously Published in The Unified Agenda Final Rule Stage No No 21 CFR 2.125 (Revision) 40 CFR 82.4 40 CFR 82.64 40 CFR 82.66 21 USC 321 21 USC 331 21 USC 335 21 USC 342 21 USC 346a 21 USC 348 21 USC 351 and 352 21 USC 355 21 USC 360b 21 USC 361 and 362 21 USC 371 and 372 21 USC 374 42 USC 7671 et seq No NPRM 06/11/2007 72 FR 32030 NPRM Comment Period End 09/10/2007 Final Action 06/00/2009 No None No No No No Martha Nguyen 0910 Food and Drug Administration FDA 301 796-3601 301 847-8440 martha.nguyen@fda.hhs.gov Center for Drug Evaluation and Research, WO 51, Room 6250, 10903 New Hampshire Avenue, Silver Spring MD 20993-0002